Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19116
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYoung, Adelaide I J-
dc.contributor.authorLaw, Andrew M K-
dc.contributor.authorCastillo, Lesley-
dc.contributor.authorChong, Sabrina-
dc.contributor.authorCullen, Hayley D-
dc.contributor.authorKoehler, Martin-
dc.contributor.authorHerzog, Sebastian-
dc.contributor.authorBrummer, Tilman-
dc.contributor.authorLee, Erinna F-
dc.contributor.authorFairlie, Walter Douglas-
dc.contributor.authorLucas, Morghan C-
dc.contributor.authorHerrmann, David-
dc.contributor.authorAllam, Amr-
dc.contributor.authorTimpson, Paul-
dc.contributor.authorWatkins, D Neil-
dc.contributor.authorMillar, Ewan K A-
dc.contributor.authorO'Toole, Sandra A-
dc.contributor.authorGallego-Ortega, David-
dc.contributor.authorOrmandy, Christopher J-
dc.contributor.authorOakes, Samantha R-
dc.date2016-12-08-
dc.date.accessioned2018-09-13T00:21:04Z-
dc.date.available2018-09-13T00:21:04Z-
dc.date.issued2016-
dc.identifier.citationBreast cancer research : BCR 2016; 18(1): 125-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19116-
dc.description.abstractMetastatic disease is largely resistant to therapy and accounts for almost all cancer deaths. Myeloid cell leukemia-1 (MCL-1) is an important regulator of cell survival and chemo-resistance in a wide range of malignancies, and thus its inhibition may prove to be therapeutically useful. To examine whether targeting MCL-1 may provide an effective treatment for breast cancer, we constructed inducible models of BIMs2A expression (a specific MCL-1 inhibitor) in MDA-MB-468 (MDA-MB-468-2A) and MDA-MB-231 (MDA-MB-231-2A) cells. MCL-1 inhibition caused apoptosis of basal-like MDA-MB-468-2A cells grown as monolayers, and sensitized them to the BCL-2/BCL-XL inhibitor ABT-263, demonstrating that MCL-1 regulated cell survival. In MDA-MB-231-2A cells, grown in an organotypic model, induction of BIMs2A produced an almost complete suppression of invasion. Apoptosis was induced in such a small proportion of these cells that it could not account for the large decrease in invasion, suggesting that MCL-1 was operating via a previously undetected mechanism. MCL-1 antagonism also suppressed local invasion and distant metastasis to the lung in mouse mammary intraductal xenografts. Kinomic profiling revealed that MCL-1 antagonism modulated Src family kinases and their targets, which suggested that MCL-1 might act as an upstream modulator of invasion via this pathway. Inhibition of MCL-1 in combination with dasatinib suppressed invasion in 3D models of invasion and inhibited the establishment of tumors in vivo. These data provide the first evidence that MCL-1 drives breast cancer cell invasion and suggests that MCL-1 antagonists could be used alone or in combination with drugs targeting Src kinases such as dasatinib to suppress metastasis.-
dc.language.isoeng-
dc.subjectBH3 mimetics-
dc.subjectBIMs2A-
dc.subjectBreast cancer-
dc.subjectCofilin-
dc.subjectInvasion-
dc.subjectMetastasis-
dc.subjectMyeloid cell leukemia-1-
dc.subjectSRC family kinase-
dc.titleMCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.-
dc.typeJournal Article-
dc.identifier.journaltitleBreast cancer research : BCR-
dc.identifier.affiliationSt. Vincent's Clinical School, UNSW Medicine, Victoria Street, Darlinghurst, NSW, 2052, Australiaen
dc.identifier.affiliationCancer Research Division, Garvan Institute of Medical Research and the Kinghorn Cancer Centre, 384 Victoria Street, Darlinghurst, NSW, 2010, Australiaen
dc.identifier.affiliationCentre for Biological Systems Analysis (ZBSA) and Centre for Biological Signallling Studies, Albert-Ludwigs-University, Stefan-Meier-Strasse 17, 79104, Freiburg, Germanyen
dc.identifier.affiliationSpemann Graduate School for Biology and Medicine and Faculty of Biology, Albert-Ludwigs-University, Stefan-Meier-Strasse 17, 79104, Freiburg, Germanyen
dc.identifier.affiliationBIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Schänzlestrasse 18, 79104, Freiburg, Germanyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine and Department of Chemistry and Physics, La Trobe University, Melbourne, Victoria, 3086, Australiaen
dc.identifier.affiliationThe Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, 3052, Australiaen
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, 3010, Australiaen
dc.identifier.affiliationDepartment of Anatomical Pathology, South Eastern Area Laboratory Service, St George Hospital, Grey St, Kogarah, NSW, 2217, Australiaen
dc.identifier.affiliationSydney Medical School, Sydney University, Fisher Rd, Camperdown, NSW, 2006, Australiaen
dc.identifier.affiliationDepartment of Tissue, Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, 2050, NSW, Australiaen
dc.identifier.doi10.1186/s13058-016-0781-6-
dc.identifier.pubmedid27931239-
dc.type.austinJournal Article-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherFairlie, Walter Douglas
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.